Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population

Biomark Med. 2017 May;11(5):413-422. doi: 10.2217/bmm-2016-0378.

Abstract

Aim: Prostate cancer and benign prostate hyperplasia (BPH) are heterogeneous disorders with high prevalence among men. The antisense noncoding RNA in the INK4 locus codes for a long noncoding RNA whose participation in cancer has been elucidated.

Method: We analyzed rs1333045, rs4977574, rs1333048 and rs10757278 genotypes from this locus in 125 prostate cancer patients, 125 BPH patients as well as 220 normal age-matched subjects by means of tetra-primer amplification refractory mutation system PCR method.

Results: The rs1333045 showed no significant difference in allele or genotype frequencies between three groups. However, the other three single nucleotide polymorphisms have been shown to be associated with BPH and prostate cancer risk.

Conclusion: Antisense noncoding RNA in the INK4 locus possibly participates in the pathogenesis of these disorders.

Keywords: ANRIL; CDKN2A/B; INK4; PCR; STAT; benign prostate hyperplasia; lncRNA; polymorphism; prostate cancer; transcription factor.

MeSH terms

  • Aged
  • Case-Control Studies
  • Humans
  • Iran
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide*
  • Prostatic Hyperplasia / genetics*
  • Prostatic Neoplasms / genetics*
  • RNA, Long Noncoding / genetics*

Substances

  • CDKN2B antisense RNA, human
  • RNA, Long Noncoding